| Prev Close | 35.45 |
| Day Low/High | 35.15 / 36.65 |
| 52 Wk Low/High | 26.95 / 52.48 |
| Avg Volume | 1.19M |
| Exchange | NASDAQ |
| Shares Outstanding | 40.71M |
| Market Cap | 1.44B |
| EPS | -1.10 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Continuous quality improvement project aims to optimize patient outcomes after hernia repair
Company working with FDA toward April 6, 2018 PDUFA date
Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the March 16th expiration.
Agreement will focus on designing and deploying best practice enhanced recovery protocols across therapeutic areas in 11 Georgia-based hospitals
Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2018 expiration.
Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals
Expanded roles reflect key accomplishments and demonstrated leadership
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the January 2018 expiration.
Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the May 2018 expiration.
The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 637,865 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 5,288,719, an increase of 13.72% since 08/15/2017.
The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent
